SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
About this episode
This episode discusses how SARS-CoV-2 mRNA vaccines may enhance the effectiveness of immune checkpoint blockade in treating tumours.
https://doi.org/10.1038/s41586-025-09655-y
People in this episode
Host: Raymond Ruff
Topics covered
- vaccines
- tumours
- immune response
- cancer therapy
- SARS-CoV-2
Keywords
- SARS-CoV-2
- mRNA vaccines
- tumours
- immune checkpoint blockade
- cancer
Mentioned in this episode
Organizations: SARS-CoV-2, mRNA vaccines, immune checkpoint blockade
Books & works: https://doi.org/10.1038/s41586-025-09655-y
More episodes of Science TLDR
- Episode 63: Engineering of acidic pH-responsive anti-CD3 binding antibodies
- Episode 62: Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study
- Episode 61: Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology
- Episode 60: A trophoblast glycoprotein specific 5 T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
- A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
- Language models cannot reliably distinguish belief from knowledge and fact
Explore listener stats, chart rankings, contacts and more on the Science TLDR podcast page.